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Transdermal drug delivery provides a mode of drug 
administration that is patient-compliant. Using 
ultrasound to the skin increases its permeability 
(sonophoresis) and creates holes that enable different 
substances to be delivered to and through the skin. 
"Transdermal Protein Delivery," examined some of 
today's most popular technologies. It also includes the 
generation of ultrasound and sonophoresis mechanism 
with special emphasis on the role of cavitation (both 
inside and outside the skin), thermal effects, convective 
transport, and mechanical effects. Sonophoresis is a 
localized, non-invasive, convenient and fast technique 
of providing drugs with low molecular weight and 
macromolecules to the skin. Transdermal biology 
delivery, as well as standard drugs, is becoming 
increasingly popular as the method provides countless 
benefits. It decreases pain, biohazardous waste and 
infection danger. Mostly, needle-free drug delivery 
generally increases patient compliance, sonophoresis 
is being investigated as a way of drawing compounds 
such as glucose out of the skin. 
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INTRODUCTION 
Transdermal Drug Transport 
Transdermal delivery includes passive 
diffusion through the skin of a drug 
substance and subsequent absorption by 
the systemic distribution capillary system. 
The primary resistance to drug diffusion 
through the skin occurs in the stratum 
corneum (SC) through a lipid pathway 
consisting of highly ordered lipid bilayers 
situated between dead disk-like cells called 
"keratinocytes". This pathway's 
physicochemical nature explains that 
stratum corneum will easily diffuse only 
lipophilic drugs. Transdermal drug 
delivery has several advantages over 
traditional methods of delivery including 
oral and injection methods. Transdermal 
delivery that traditionally uses a patch 
containing drug substance pressed onto the 
skin is non-invasive, convenient and 
painless and can prevent gastrointestinal 
toxicity (e.g., peptic ulcer disease), 
gastrointestinal degradation (e.g., insulin-
 
 
14 Page 13-22 © MAT Journals. All Rights Reserved 
 
Journal of Pharmacological Research and Developments 
e-ISSN: 2582-0117  
Volume 2, Issue 1 
 
like polypeptides) and first-pass hepatic 
metabolism. Few drugs can penetrate 
the skin at rates that are sufficient to 
produce therapeutic plasma levels using 
traditional methods of transdermal 
delivery; these drugs are either of 
relatively low molecular weight (< 250 
Da), such as Nicotine and nitroglycerin, 
or of higher molecular weight (> 250 
but < 500 Da), such as fentanyl, 
estradiol, and testosterone, have a high 
therapeutic potential and are therefore 
effective at low delivery rates.  
Transdermal delivery of much higher 
molecular weight (> 500 Da) drugs 
requires mechanisms for improving skin 
permeation. Several methods have been 
suggested to facilitate and increase the 
delivery rate through the epidermis of 
higher molecular weight drugs. These 
methods include the use of chemical 
enhancements (a) iontophoresis (b) 
electroporation (c) sonophoresis 
(phonophoresis), when ultrasound is 
used to drive a topically applied 
medication's molecules [1, 2]. 
 
 
Figure 1: Absorption of the drug by sonophoresis. 
 
CLASSIFICATION OF 
TRANSDERMAL DRUG DELIVERY 
SYSTEM [3]
 
Rate Programmed Systems  
(a) reservoir drugs 
(b) matrix drugs  
(c) adhesive drugs 
(d) Micro reservoir drug  
 
Physical-Stimulated Systems  
(a) structural systems 
(b) electrical systems  
(c) iontophoresis 




Sonophoresis is the movement of drug 
molecules under the influence of 
ultrasound through the skin. This method 
utilizes less than 100 kHz low-frequency 
pressure waves. Ultrasound application to 
the skin can interfere with the bilayer of 
the stratum corneum lipid. As a result, 
drug molecules can more easily permeate 
the skin. 
 
It is a process that increases the absorption 
of topical compounds in the epidermis, 
dermis and skin appendages exponentially 
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(transdermal delivery). Sonophoresis 
occurs because ultrasound waves in the 
skin epidermis stimulate micro-vibrations 
and increase the overall kinetic energy of 
molecules that make up topical agents. It is 
widely used for the delivery of drugs 
through the skin in hospitals. Pharmacists 
mix the drugs with a coupling agent (gel, 
cream, ointment) to transfer ultrasonic 
energy from the ultrasound transducer to 
the skin. Besides its impact on the delivery 
of compounds to the skin, sonophoresis is 
explored as a manner to extract 
compounds like glucose from the skin. 
Ultrasound produces skin holes and 
enables the flow of liquids into or out of 
the body. "The sound waves disturb the 
lipid bilayers when sound is emitted at a 
specific frequency," Mitragotri said. He 
pointed out that for the transdermal 
delivery of biologics the ideal ultrasound 
frequency range is 50-60 kHz [4, 5]. 
 
In the topical delivery of tiny molecules 
such as lidocaine, sonophoresis has been 
effective in inducing local anesthesia. 
Since this method is non-invasive and 
painless, the transdermal delivery of 
macromolecules is being explored.  
 
Sonophoresis equipment is made up of a 
piezoelectric crystal and a coupling 
medium. Ultrasound is produced when a 
piezoelectric crystal converts electrical 
energy into mechanical energy 
(oscillations), thus generating acoustic 
waves. Ultrasound application results in 
the formation of microbubbles in the 
coupling medium. The collapse of these 
bubbles on the stratum corneum surface 
results in shock waves that make the skin 
permeable. It is also possible to produce 
acoustic microjets that behave by 
impacting or even touching the surface of 
the stratum corneum. Other mechanisms 
such as thermal effects and radiation 
pressure were also suggested to have some 
effect on the enhancement of sonophoresis 
permeation. 
The current-use equipment is the 
SonoPrepTM System and the cymbal array 
transducer. U.S. Food and Drug 
Administration (FDA) has approved the 
SonoPrep System for topical delivery of 
lidocaine to induce local anesthesia. The 
wearable cymbal ultrasound transducer is 
also under development [6, 7]. 
 
GENERATION OF ULTRASOUND 
Ultrasound is a sound with frequencies 
greater than 20 kHz. These waves are 
characterized by the frequencies and 
amplitude of two main parameters. 
Ultrasound amplitude may be represented 
in terms of peak wave pressure (in 
Pascal's) or intensity terms (in W / cm2 
units). Either continuously or pulsed, 
ultrasound can be applied. Using a device 
called a sonicator, ultrasound is produced. 
It comprises of an electrical signal 
produced at the required frequency and 
amplitude that produces an electrical AC 
signal. This signal is applied across a 
piezoelectric crystal (transducer) to 
generate the operating frequency's 
ultrasonic thickness [8]. 
 
If there is no commercially accessible 
sonicator running at the required 
frequency, one can be assembled using 
commercially accessible signal generators, 
amplifiers, and transducers. Ultrasound is 
applied to ensure proper contact between 
the transducer and the skin by contacting 
the transducer with the skin through a 
coupling medium. This medium may be 
the same as the solvent used to dissolve 
the drug or it may be a commercially 
available ultrasonic coupling gel (e.g. 
Aquasonic, Polar, NJ) There are three 
distinct sets of ultrasonic conditions based 
on frequency range and applications: 
 In clinical imaging, high-frequency or 
diagnostic ultrasound (3–10 MHz).  
 Physical therapy with medium or 
therapeutic ultrasound (0.7–3.0 MHz).  
 Ultrasound with low frequency or 
energy for lithotripsy, cataract 
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emulsification, liposuction, cancer 
treatment, dental scaling and ultrasonic 




 Improved penetration of drugs 
(selected drugs) by passive transport.  
 It allows strict control of transdermal 
rates of penetration.  
 Low risk of infection as the skin stays 
intact.  
 Reduced dosing frequency and 
compliance with patients. 
  Improved control of drug 
concentrations with small indices of 
therapy. 
 Reduction of drug plasma levels 
fluctuations. 
 Evicting first-pass hepatic removal and 
gastrointestinal irritation. 
 Replaces oral administration when the 
route is inappropriate as in the case of 
vomiting, diarrhea. 
 Allow local and systemic impacts and 
reduce the risk of systemic absorption 
compared to injection.  
 Easy termination of the delivery of 
drugs in the event of toxicity, by 
ending ultrasound.  
  Rapid identification of medication in 




 Stratum corneum must be intact for 
effective drug penetration. 
 It may take time to administer it.  
 Minor tingling, irritation and burning 
have been reported (these effects can 
often be minimized or eradicated with 




Sonophoresis has been used to administer 
many drugs. Hydrocortisone is the most 
frequently used drug in concentrations 
ranging from 1% to 10%. Other drugs used 
include betamethasone, 
oligodeoxynucleotides, alpha chymotrypsin, 
dexamethasone, fluocinonide, heparin, 
hyaluronidase, ibuprofen, indomethacin, 
insulin, iodine, ketoprofen, lidocaine, 
naproxen piroxicam, sodium salicylate, 




It is important to identify the different 
effects of ultrasound exposure on human 
tissue to understand the mechanisms of 
sonophoresis. Upon exposure to ULTS, 
various phenomena may occur in the skin. 
This includes: 
a) cavitation effects  
b) thermal effects  
c) convective transport induction 
 d) mechanical effects. 
 
Cavitation Effects 
Cavitation is gaseous cavity formation in 
medium ULTS exposure. The primary 
cause of cavitation is ULTS-induced 
medium pressure variation. Cavitation 
involves either the rapid growth and 
collapse of a bubble (inertial cavitation) or 
the slow movement of a bubble in a ULTS 
field. The collapse of cavitation bubbles 
releases a shock wave in the surrounding 
tissue which can cause structural changes. 
ULTS can generate violent micro streams 
that increase the drug's bioavailability. 
Tissues contain air pockets trapped in 
fibrous structures that act as nuclei for 
cavitation after exposure to ultrasound. 
The effects of cavitation vary inversely 
with ULTS frequency and directly with 
ULTS intensity. Cavitation may be 
important when using low-frequency 
ULTS, exposing gassy fluids, or when 
exposing small gas-filled spaces. 
Cavitation is caused by the nucleation of 
small gaseous cavities during the ULTS 
negative pressure cycles, followed by the 
growth of these bubbles during subsequent 
pressure cycles [16, 17]. 
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Figure 2: Picture of how ultrasound disrupts the stratum corneum. 
 
 
Figure 3: Schematic sketch of cavitation occurring in the keratinocytes. Cavitation occurs 
preferentially at the interface between the keratinocytes and lipid bilayer. 
 
Thermal Effects 
ULTS absorption increases medium 
temperature. Materials with higher ULTS 
absorption coefficients, such as bone, have 
severe thermal effects compared to muscle 
tissue, which has a lower coefficient of 
absorption. The increase in medium 
temperature at a given frequency after 
ULTS exposure varies directly with ULTS 
intensity and exposure time. ULTS 
frequency directly increases the absorption 
coefficient of the medium, resulting in 
temperature increase. A study suggested 
using a new parameter of safety, time to 
the threshold (TT). TT indicates when a 
threshold temperature rise is exceeded and 
how long a piece of tissue may be exposed 
to ULTS safely, provided the safe 




Velocities of fluid are generated in porous 
media exposed to ULTS due to incident 
interference and reflected ULTS waves in 
 
 
18 Page 13-22 © MAT Journals. All Rights Reserved 
 
Journal of Pharmacological Research and Developments 
e-ISSN: 2582-0117  
Volume 2, Issue 1 
 
the diffusion cell and cavitation bubble 
oscillations. The fluid speeds thus 
generated can affect transdermal transport 
by inducing convective transport of the 
permanent through the skin, particularly 
through hair follicles and sweat ducts. 
Experimental findings suggest that 
convective transport does not play an 
important role in the observed transdermal 
enhancement [19, 20]. 
 
Mechanical Effects 
ULTS is a longitudinal pressure wave that 
induces sinusoidal pressure variations in 
the skin, which in turn induces variations 
in sinusoidal density. The density 
variations occur so rapidly at frequencies 
greater than 1 MHz that a small gaseous 
nucleus can not develop and cavitational 
effects stop. But other effects may 
continue to occur due to variations in 
density, such as the generation of cyclic 
stresses due to changes in density that 
ultimately lead to medium fatigue. These 
stresses can easily disorder lipid bilayers, 
being self-assembled structures, which 
increases the permeability of the bilayer. 
This increase is non-significant, however, 
and thus mechanical effects do not play an 
important role in therapeutic sonophoresis. 
Thus, cavitation-induced lipid bilayer 
disorder is found to be the most important 
cause of transdermal transport ultrasonic 
enhancement. Drug delivery For the actual 
delivery of drugs, two different approaches 
are used. The drug-containing coupling 
agent was originally applied to the skin 
immediately followed by the treatment 
with ultrasound. Today, the product is 
generally applied to the skin and the drug 
may start absorption into the skin for a 
period of time; then the ultrasound is 
applied. Drug penetration in the 1 to 2 




Contraindications and/or precautions for 
ultrasound and phonophoresis include:  
● infection,  
● cancer, 
● heart problems/pacemaker, 
● implants (metal, silicone, saline),  
● acute and post-acute injury,  
● epiphysis,  
● pregnancy,  
● thrombophlebitis,  





 Ultrasound helps treat elbow tennis 
and tendon problems. 
 Sonophoresis is used to treat damaged 
skin. 
 The painful condition of the muscle 
responds to non-invasive ultrasound 
treatment.  
 Hormone ultrasound delivery with 
topical anesthesia rapidly decreases 
intravenous cannulation pain. 
 Low-frequency ultrasonic gene 
delivery. 
 Ultrasound for calcific shoulder 
tendinitis. 





In recent years, much attention has been 
given to the potential to exploit the skin 
for vaccination purposes. Transcutaneous 
immunization provides access to the skin's 
immune system, where densely distributed 
and potent antigen-presenting cells 
(Langerhans cells) dominate. It has been 
shown that Langerhans cells play essential 
roles in inducing T-cell-mediated immune 
reactions to a wide range of antigens. The 
vaccine, which is usually a large molecule 
or complex, must penetrate the stratum 
corneum barrier to make this technique 
practical. Normally, under these 
conditions, the skin is not permeable. A 
popular approach is to use an adjuvant, a 
compound used to improve the immune 
response to compounds of the vaccine. The 
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application of cholera toxin to the skin 
surface stimulates an immune response to 
vaccine compounds such as toxoid from 
diphtheria or tetanus. The use of physical 
enhancers such as ultrasound is another 
approach. Ultrasound can be used to 
improve the permeability of the skin to 
both the adjuvant and the vaccine, thus 




Gene Therapy  
The field of topical gene therapy is another 
potential application for ultrasound as a 
topical enhancer that appears to be 
promising. Gene therapy is a technique 
used to correct defective genes responsible 
for the development of the disease, most 
commonly by replacing an' abnormal' 
disease-causing gene with the' normal' 
gene. The therapeutic gene is generally 
delivered to the target cell by a carrier 
molecule (vector). Topical vector–gene 
complex delivery can be used both for 
target cells in the skin and for systemic 
circulation. Identifying genes responsible 
for nearly 100 skin-affected diseases has 
made it possible to use cutaneous gene 
therapy as a therapeutic method. Severe 
forms of specific genodermatoses 
(monogenic skin disorders), such as 
epidermolysis bullosa and ichthyosis, are 
the most obvious candidate diseases for 
cutaneous gene therapy. Other applications 
may include the healing of skin wounds 
such as severe burns and diabetic-origin 
skin wounds. Topical gene therapy 
acquires the penetration of a big complex 
into or through the skin. Pre-treatment of 
the skin by ultrasound will improve its 
permeability and allow the carrying vector 




The usefulness of ultrasound as a technical 
tool in medicine as well as a therapeutic 
agent is increasing steadily. In perspective 
of this, there is a great deal of concern 
about the problems of bioeffects and safety 
in ultrasound. Several articles on the safety 
of ultrasound bioeffects have been 
published by the World Federation for 
Ultrasound in Medicine and Biology 
(WFUMB; http:/www.wfumb.org). The 
use of ultrasound as an aid to increase skin 
permeability is based on its non-thermal 
bioeffects, mostly cavitation. In order to 
develop a useful tool based on ultrasound 
technology, further research on safety 
issues is needed to assess the limiting 




RECOVERY OF THE SKIN BARRIER 
PROPERTIES AFTER 
SONOPHORESIS 
There are numerous reports that the use of 
therapeutic ultrasound (1-3 MHz, 0-2W / 
cm2) does not cause irreversible changes 
in the permeability of the skin in vivo 
drugs. Quantitative measurement of 
estradiol transportation across human skin 
(in vitro) has also shown that the use of 
therapeutic ultrasound (1 MHz, 2W / cm2) 
does not induce any statistically significant 
irreversible changes in the properties of 
skin barriers. Similar experiments have 
also been conducted using very low-
frequency ultrasound (20 kHz, 125mW / 
cm2, 100ms pulse applied every second) to 
evaluate whether the application of low-
frequency ultrasound results in any 
continuous loss of the barrier 
characteristics of skin measured in terms 
of water permeability. It was found that 
the skin permeability to water measured in 
2h post-exposure was comparable to the 
passive skin permeability 2 h post-
exposure was about 6 times higher than the 
passive water permeability in the case of 1 
h long ultrasound exposure. This value, 
however, contained a decrease and was 12 
h post-exposure within a factor of 2 of the 
passive skin water permeability. Studies 
have also been carried out to evaluate 
whether the use of greater frequency 
ultrasound induces irreversible harm to the 
barrier characteristics of the skin as 
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measured in terms of trans-epidermal 
water loss (TEWL) across hairless skin of 
mice subjected to high frequency. No 
important distinction was found in 
ultrasound-exposed skin TEWL values and 




Ultrasound application improves the 
transport of transdermal drugs, a 
phenomenon known as sonophoresis. For 
efficient sonophoresis, proper choice of 
ultrasound parameters including 
ultrasound energy dose, frequency, 
intensity, pulse length, and skin distance is 
critical. The numerous attempts made over 
the past 50 years can be classified into 
three categories; high-frequency 
therapeutic frequency and low-frequency 
ultrasound; the first is the most frequently 
used ultrasound condition for 
sonophoresis, although recent attention has 
focused more on low and high-frequency 
conditions. Mechanism experiments 
conducted by multiple investigations 
suggest that cavitation disorganizes the 
skin's lipid bilayers through which 
increased drug transport can occur. 
Different trials have shown that applying 
ultrasound under circumstances used for 
sonophoresis does not cause permanent 
skin harm or further research is needed at a 
definite conclusion before reaching a 
definite conclusion on the safety of 
ultrasound exposure. It has been shown 
that low-frequency sonophoresis increases 
the permeability of the skin to a variety of 
low-and high-molecular-weight medicines 
including insulin and low-molecular 
heparin. Ultrasound-mediated transdermal 
transport enhancement is mediated through 
inertial cavitation. Because of cavitation-
generated shock waves or microjets, the 
collapse of cavitation bubbles near the 
stratum corneum is assumed to disrupt its 
structure. Ultrasound also works with 
several other enhancers including 
chemicals and iontophoresis in a 
synergistic way.  
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